NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat.com ...

DelveInsight’s, “HDAC Inhibitor Pipeline Insight” report provides comprehensive insights about 40+ companies and 50+ pipeline ...

A live webcast of the presentation can be accessed under "Events and Presentations" in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be ...

Chief Executive Officer of Amylyx Pharmaceuticals , Inc. (NASDAQ:AMLX), sold 11,855 shares of common stock. The company, currently valued at $246 million, has received a "GOOD" financial health rating ...

Founded in 1935 by Khwaja Abdul Ahmeid, Cipla operates through two segments: Pharmaceuticals and New Ventures. Cipla Limited specialises in developing medications, primarily treating respiratory ...

Amylyx Pharmaceuticals (AMLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

In a 13G filing on Amylyx Pharmaceuticals (AMLX), Steven Cohen's hedge fund Point72 Asset Management, L.P. disclosed a 5.1%, or 3,470,691 share, stake in the company. For more... Amylyx ...

We would like to share some important news with you. After years of bringing you the latest insights, analysis and innovation news from the pharma industries, we have made the difficult decision to ...

The two drugs haven’t been directly tested against each other, however. BridgeBio could also soon have as a third competitor Alnylam Pharmaceuticals, which has different type of therapy under review ...